Dinutuximab med kemoterapi, kirurgi og stamcelletransplantation til behandling af børn med nyligt diagnosticeret højrisikoneuroblastom
Et fase 3-studie af dinutuximab tilføjet til intensiv multimodal terapi til børn med nyligt diagnosticeret højrisikoneuroblastom
This phase III trial tests how well the addition of dinutuximab to Induction chemotherapy along with standard of care surgical resection of the primary tumor, radiation, stem cell transplantation, and immunotherapy works for treating children with newly diagnosed high-risk neuroblastoma. Dinutuximab is a monoclonal antibody that binds to a molecule called GD2, which is found on the surface of neuroblastoma cells, but is not present on many healthy or normal cells in the body. When dinutuximab binds to the neuroblastoma cells, it helps signal the immune system to kill the tumor cells. This helps the cells of the immune system kill the cancer cells, this is a type of immunotherapy. When chemotherapy and immunotherapy are given together, during the same treatment cycle, it is called chemoimmunotherapy. This clinical trial randomly assigns patients to receive either standard chemotherapy and surgery or chemoimmunotherapy (chemotherapy plus dinutuximab) and surgery during Induction therapy. Chemotherapy drugs administered during Induction include, cyclophosphamide, topotecan, cisplatin, etoposide, vincristine, and doxorubicin. These drugs work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing or by stopping them from spreading. Upon completion of 5 cycles of Induction therapy, a disease evaluation is completed to determine how well the treatment worked. If the tumor responds to therapy, patients receive a tandem transplantation with stem cell rescue. If the tumor has little improvement or worsens, patients receive chemoimmunotherapy on Extended Induction. During Extended Induction, dinutuximab is given with irinotecan, temozolomide. Patients with a good response to therapy move on to Consolidation therapy, when very high doses of chemotherapy are given at two separate points to kill any remaining cancer cells. Following, transplant, radiation therapy is given to the site where the cancer originated (primary site) and to any other areas that are still active at the end of Induction. The final stage of therapy is Post-Consolidation. During Post-Consolidation, dinutuximab is given with isotretinoin, with the goal of maintaining the response achieved with the previous therapy. Adding dinutuximab to Induction chemotherapy along with standard of care surgical resection of the primary tumor, radiation, stem cell transplantation, and immunotherapy may be better at treating children with newly diagnosed high-risk neuroblastoma.
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
- Medicin: Carboplatin
- Medicin: Cyclophosphamide
- Medicin: Cisplatin
- Procedure: Bone Marrow Biopsy
- Medicin: Doxorubicin
- Medicin: Vincristine
- Procedure: Magnetic Resonance Imaging
- Procedure: Echocardiography Test
- Procedure: Multigated Acquisition Scan
- Procedure: Bone Marrow Aspiration
- Medicin: Etoposide
- Procedure: Computed Tomography
- Medicin: Topotecan
- Stråling: Radiation Therapy
- Procedure: Biospecimen Collection
- Andet: Survey Administration
- Medicin: Melphalan
- Medicin: Irinotecan
- Medicin: Thiotepa
- Biologisk: Dinutuximab
- Procedure: FDG-Positron Emission Tomography and Computed Tomography Scan
- Procedure: Hematopoietic Cell Transplantation
- Medicin: Isotretinoin
- Procedure: Leukapheresis
- Procedure: Radionuclide Imaging
- Medicin: Temozolomide
- Procedure: Tumor Resection
Detaljeret beskrivelse
PRIMARY OBJECTIVE:
I. To determine if the event-free survival (EFS) of patients with newly diagnosed high-risk neuroblastoma assigned to early chemoimmunotherapy during Induction differs from that of patients who are not assigned to treatment that includes early chemoimmunotherapy.
SECONDARY OBJECTIVES:
I. To determine if early chemoimmunotherapy during Induction therapy improves end of Induction (EOI) response rates and overall survival (OS) for patients with newly diagnosed high-risk neuroblastoma.
II. To determine response rates, EFS, and OS following an Extended Induction regimen with chemoimmunotherapy in patients with progressive disease or a poor response to Induction therapy.
III. To compare the toxicities experienced by patients treated with chemoimmunotherapy during Induction versus those experienced by patients treated with standard Induction and to describe toxicities experienced during Extended Induction.
IV. To determine GD2 expression on tumor tissue and tumor cells in bone marrow and assess for associations with response and outcome.
EXPLORATORY OBJECTIVES:
I. To describe the association between tumor and host factors and outcomes in patients receiving protocol therapy.
II. To evaluate circulating biomarkers and markers of minimal residual disease at baseline and during therapy, and assess for associations with response and outcome.
III. To compare patterns of failure between patients treated with and without dinutuximab during induction.
IV. To determine the effect of telomere maintenance mechanisms on end of Induction response rates, EFS, and OS.
V. To explore the impact of high-risk neuroblastoma (HRNBL) and its therapy, including the addition of dinutuximab to Induction chemotherapy, on functional and quality of life outcomes in patients with HRNBL, as measured by caregiver (parent/legal guardian) and patient questionnaires.
VI. To describe the adequacy of diagnostic biopsy specimens, including those obtained by percutaneous core needle biopsy.
VII. To explore the associations between family-reported adverse social determinants of health and both clinical outcomes and biology.
VIII. To develop and validate deep learning predictors of Induction response based on diagnostic MIBG scans. (Imaging Objective) IX. To compare institutional versus central determination of overall response, individual response components (primary tumor, soft tissue and bone metastatic disease, and bone marrow metastatic disease), and poor end of induction response (PEIR) and good end of induction response (GEIR) determination. (Imaging Objective) X. To describe late toxicities (including impaired organ function, neuropsychiatric toxicity, and incidence of secondary malignancy) in patients treated with dinutuximab during Induction or Extended Induction to late toxicities in patients who have not received dinutuximab during these phases of therapy.
XI. To evaluate whether reduced dose radiotherapy to the primary site clinical target volume (CTV) in patients with complete response of the primary site at EOI results in comparable local control relative to historical cohorts.
XII. To compare post-transplant complications between treatment arms, and assess for associations with outcome.
XIII. To assess for associations between EOI response (including good end of Induction response [GEIR] and poor end of Induction response [PEIR]) and individual response components (primary tumor, soft tissue and bone metastatic disease, and bone marrow metastatic disease) with outcome (EFS and OS).
XIV. To describe and compare the changes in image-defined risk factors (IDRFs) between patients treated with and without dinutuximab during Induction and associate with surgical outcomes and local failure rates following primary tumor resection.
XV. To bank serial samples of blood, bone marrow, and tumor tissue for future research.
OUTLINE: Patients receive Induction cycle 1 and are then randomized to 1 of 2 treatment arms.
INDUCTION CYCLE 1: Patients receive cyclophosphamide intravenously (IV) over 30 minutes and topotecan IV over 30 minutes on days 1-5 in the absence of unacceptable toxicity.
ARM A:
INDUCTION CYCLES 2-5: Patients receive cyclophosphamide IV over 30 minutes and topotecan IV over 30 minutes on days 1-5 of cycle 2 in the absence of unacceptable toxicity. Patients then undergo stem cell harvest via apheresis. Patients then receive cisplatin IV over 4 hours and etoposide IV over 2 hours on days 1-3 of cycles 3 and 5, and vincristine IV on day 1, doxorubicin IV over 15 minutes, and cyclophosphamide IV over 1 hour on days 1-2 of cycle 4 in the absence of unacceptable toxicity. Patients undergo primary tumor resection after Induction cycle 4 or 5. Following Induction cycle 5, patients undergo testing to determine response to Induction therapy. Patients with a good tumor response proceed to Consolidation, while patients with a poor tumor response proceed to Extended Induction.
EXTENDED INDUCTION: Patients with a poor tumor response or progression during Induction receive temozolomide orally (PO), via nasogastric tube (NG), or via gastric tube (G-tube) on days 1-5, irinotecan IV over 90 minutes on days 1-5, and dinutuximab IV over 10 hours. Treatment repeats every 21 days for up to a maximum of 6 cycles in the absence of disease progression or unacceptable toxicity. If at any time during Extended Induction testing shows a good tumor response, patients proceed to Consolidation. If after 6 cycles of Extended Induction or if at any time progression is noted, patients are removed from the study.
CONSOLIDATION: Patients undergo two autologous hematopoietic stem cell transplantations (HSCTs) during Consolidation. Patients receive thiotepa IV over 2 hours on days -7 to -5 and cyclophosphamide IV over 1 hour on days -5 to -2 during HSCT 1. Patients then receive stem cell infusion IV on day 0. Between 6 and 10 weeks after stem cell infusion, patients receive melphalan IV over 30 minutes on days -7 to -5, etoposide IV over 24 hours on days -7 to -4, and carboplatin over 24 hours on days -7 to -4 during HSCT 2. Patients receive stem cell infusion IV on day 0. Between day +42 and day +80 after HSCT 2. Patients receive radiation daily for 12 treatments in the absence of disease progression or unacceptable toxicity.
POST CONSOLIDATION: Patients receive dinutuximab IV over 10 hours on days 4-7 and isotretinoin PO twice daily (BID) on days 11-24 of cycles 1-5. Treatment repeats every 28 days for up to 5 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive isotretinoin PO BID on days 15-28 for 1 additional cycle, cycle 6.
Patients undergo blood and urine sample collection, echocardiogram (ECHO) or multigated acquisition scan (MUGA), bone marrow aspiration and/or biopsy, computed tomography (CT) scan, magnetic resonance imaging (MRI), iodine-123 meta-iodobenzylguanidine (I-MIBG) scan and possible fluorodeoxyglucose position emission tomography (FDG-PET) scan throughout the study.
ARM B:
INDUCTION CYCLES 2-5: Patients receive cyclophosphamide IV over 30 minutes, topotecan IV over 30 minutes on days 1-5, and dinutuximab IV over 10 hours on days 2-5 of cycle 2 in the absence of unacceptable toxicity. Patients then undergo stem cell harvest via apheresis. Patients receive cisplatin IV over 4 hours and etoposide IV over 2 hours on days 1-3 and dinutuximab IV over 10 hours on days 2-5 of cycles 3 and 5, and vincristine IV on day 1, doxorubicin IV over 15 minutes, and cyclophosphamide IV over 1 hour on days 1-2, and dinutuximab IV over 10 hours on days 2-5 of cycle 4 in the absence of unacceptable toxicity. Patients undergo primary tumor resection after Induction cycle 4 or 5. Following Induction cycle 5, patients undergo testing to determine response to Induction therapy. Patients with a good tumor response proceed to Consolidation, while patients with a poor tumor response proceed to Extended Induction.
EXTENDED INDUCTION: Patients with a poor tumor response or progression during Induction receive temozolomide PO, via NG tube, or via G-tube on days 1-5, irinotecan IV over 90 minutes on days 1-5, and dinutuximab IV over 10 hours. Treatment repeats every 21 days for up to a maximum of 6 cycles in the absence of disease progression or unacceptable toxicity. If at any time during Extended Induction testing shows a good tumor response, patients proceed to Consolidation. If after 6 cycles of Extended Induction or if at any time progression is noted, patients are removed from the study.
CONSOLIDATION: Patients undergo two autologous HSCTs during Consolidation. Patients receive thiotepa IV over 2 hours on days -7 to -5 and cyclophosphamide IV over 1 hour on days -5 to -2 during HSCT 1. Patients then receive stem cell infusion IV on day 0. Between 6 and 10 weeks after stem cell infusion patients receive melphalan IV over 30 minutes on days -7 to -5, etoposide IV over 24 hours on days -7 to -4, and carboplatin over 24 hours on days -7 to -4 during HSCT 2. Patients receive stem cell infusion IV on day 0. Between day +42 and day +80 after HSCT 2, patients receive radiation daily for 12 treatments in the absence of disease progression or unacceptable toxicity.
POST CONSOLIDATION: Patients receive dinutuximab IV over 10 hours on days 4-7 and isotretinoin PO BID on days 11-24 of cycles 1-5. Treatment repeats every 28 days for up to 5 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive isotretinoin PO BID on days 15-28 for 1 additional cycle, cycle 6.
Patients undergo blood and urine sample collection, ECHO or MUGA, bone marrow aspiration and/or biopsy, CT scan, MRI, I-MIBG scan and possible FDG-PET scan throughout the study.
After completion of study treatment, patients are followed up at 3, 6, 9,12, 15, 18, 24, 30, 36, 42, 48, 54, and 60 months and then periodically for up to 10 years from enrollment.
Undersøgelsestype
Undersøgelsestype
Tilmelding (Anslået)
Tilmelding
Fase
Fase
- Fase 3
Kontakter og lokationer
Studiesteder
-
-
New South Wales
-
Randwick, New South Wales, Australien, 2031
- Rekruttering
- Sydney Children's Hospital
-
Ledende efterforsker:
- Draga Barbaric
-
Kontakt:
- Site Public Contact
- Telefonnummer: (02) 9382-1721
-
Westmead, New South Wales, Australien, 2145
- Rekruttering
- The Children's Hospital at Westmead
-
Kontakt:
- Site Public Contact
- Telefonnummer: 61-2-9845 1400
-
Ledende efterforsker:
- Bhavna Padhye
-
-
Queensland
-
South Brisbane, Queensland, Australien, 4101
- Rekruttering
- Queensland Children's Hospital
-
Ledende efterforsker:
- Steven A. Foresto
-
Kontakt:
- Site Public Contact
- Telefonnummer: 61 7 3068 1111
-
-
Victoria
-
Parkville, Victoria, Australien, 3052
- Rekruttering
- Royal Children's Hospital
-
Ledende efterforsker:
- Martin A. Campbell
-
Kontakt:
- Site Public Contact
- Telefonnummer: 61 3 9345 5656
- E-mail: Jordan.Hansford@rch.org.au
-
-
Western Australia
-
Perth, Western Australia, Australien, 6009
- Rekruttering
- Perth Children's Hospital
-
Kontakt:
- Site Public Contact
- E-mail: helpdesk@childrensoncologygroup.org
-
Ledende efterforsker:
- Michelle Ng
-
-
-
-
-
Québec, Canada, G1V 4G2
- Rekruttering
- CHU de Quebec-Centre Hospitalier de l'Universite Laval (CHUL)
-
Ledende efterforsker:
- Bruno Michon
-
Kontakt:
- Site Public Contact
- Telefonnummer: 418-525-4444
- E-mail: rechclinique@crchudequebec.ulaval.ca
-
-
Alberta
-
Calgary, Alberta, Canada, T3B 6A8
- Rekruttering
- Alberta Children's Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 403-220-6898
- E-mail: research4kids@ucalgary.ca
-
Ledende efterforsker:
- Victor A. Lewis
-
Edmonton, Alberta, Canada, T6G 2B7
- Rekruttering
- University of Alberta Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 780-407-8798
- E-mail: pedsoncologyresearch@ahs.ca
-
Ledende efterforsker:
- Sarah J. McKillop
-
-
British Columbia
-
Vancouver, British Columbia, Canada, V6H 3V4
- Rekruttering
- British Columbia Children's Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 6477 604-875-2345
-
Ledende efterforsker:
- Rebecca J. Deyell
-
-
Manitoba
-
Winnipeg, Manitoba, Canada, R3E 0V9
- Rekruttering
- CancerCare Manitoba
-
Kontakt:
- Site Public Contact
- Telefonnummer: 866-561-1026
- E-mail: ctu_web@cancercare.mb.ca
-
Ledende efterforsker:
- Stephanie M. Villeneuve
-
-
Newfoundland and Labrador
-
St. John's, Newfoundland and Labrador, Canada, A1B 3V6
- Rekruttering
- Janeway Child Health Centre
-
Ledende efterforsker:
- Lisa A. Goodyear
-
Kontakt:
- Site Public Contact
- Telefonnummer: 709-777-8727
- E-mail: beverlyj.mitchell@easternhealth.ca
-
-
Nova Scotia
-
Halifax, Nova Scotia, Canada, B3K 6R8
- Rekruttering
- IWK Health Centre
-
Kontakt:
- Site Public Contact
- Telefonnummer: 902-470-8520
- E-mail: Research@iwk.nshealth.ca
-
Ledende efterforsker:
- Chelsea Ash
-
-
Ontario
-
Hamilton, Ontario, Canada, L8N 3Z5
- Rekruttering
- McMaster Children's Hospital at Hamilton Health Sciences
-
Kontakt:
- Site Public Contact
- Telefonnummer: 905-521-2100
-
Ledende efterforsker:
- Uma H. Athale
-
London, Ontario, Canada, N6A 5W9
- Rekruttering
- Children's Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 519-685-8306
-
Ledende efterforsker:
- Shayna M. Zelcer
-
Ottawa, Ontario, Canada, K1H 8L1
- Rekruttering
- Children's Hospital of Eastern Ontario
-
Kontakt:
- Site Public Contact
- Telefonnummer: 613-737-7600
-
Ledende efterforsker:
- Donna L. Johnston
-
Toronto, Ontario, Canada, M5G 1X8
- Rekruttering
- Hospital for Sick Children
-
Kontakt:
- Site Public Contact
- Telefonnummer: 416-813-7654
- E-mail: ask.CRS@sickkids.ca
-
Ledende efterforsker:
- Daniel A. Morgenstern
-
-
Quebec
-
Montreal, Quebec, Canada, H3H 1P3
- Rekruttering
- The Montreal Children's Hospital of the MUHC
-
Kontakt:
- Site Public Contact
- Telefonnummer: 514-412-4445
- E-mail: info@thechildren.com
-
Ledende efterforsker:
- Stephanie Mourad
-
Montreal, Quebec, Canada, H3T 1C5
- Rekruttering
- Centre Hospitalier Universitaire Sainte-Justine
-
Ledende efterforsker:
- Monia Marzouki
-
Kontakt:
- Site Public Contact
- Telefonnummer: 514-345-4931
- E-mail: yvan.samson@umontreal.ca
-
Sherbrooke, Quebec, Canada, J1H 5N4
- Rekruttering
- Centre Hospitalier Universitaire de Sherbrooke-Fleurimont
-
Kontakt:
- Site Public Contact
- Telefonnummer: 819-820-6480
- E-mail: crcinformation.chus@ssss.gouv.qc.ca
-
Ledende efterforsker:
- Stephanie Vairy
-
-
Saskatchewan
-
Saskatoon, Saskatchewan, Canada, S7N 0W8
- Rekruttering
- Jim Pattison Children's Hospital
-
Ledende efterforsker:
- Kathleen Felton
-
Kontakt:
- Site Public Contact
- Telefonnummer: 306-655-3544
- E-mail: Jessica.Marien@saskhealthauthority.ca
-
-
-
-
Alabama
-
Birmingham, Alabama, Forenede Stater, 35233
- Rekruttering
- Children's Hospital of Alabama
-
Kontakt:
- Site Public Contact
- Telefonnummer: 205-638-9285
- E-mail: oncologyresearch@peds.uab.edu
-
Ledende efterforsker:
- Elizabeth D. Alva
-
Mobile, Alabama, Forenede Stater, 36604
- Rekruttering
- USA Health Strada Patient Care Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-388-8721
-
Ledende efterforsker:
- Hamayun Imran
-
-
Arizona
-
Mesa, Arizona, Forenede Stater, 85202
- Rekruttering
- Banner Children's at Desert
-
Kontakt:
- Site Public Contact
- Telefonnummer: 480-412-3100
-
Ledende efterforsker:
- Joseph C. Torkildson
-
Phoenix, Arizona, Forenede Stater, 85016
- Rekruttering
- Phoenix Childrens Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 602-546-0920
-
Ledende efterforsker:
- Alok K. Kothari
-
Tucson, Arizona, Forenede Stater, 85719
- Rekruttering
- Banner University Medical Center - Tucson
-
Kontakt:
- Site Public Contact
- E-mail: UACC-IIT@uacc.arizona.edu
-
Ledende efterforsker:
- Monica M. Davini
-
-
Arkansas
-
Little Rock, Arkansas, Forenede Stater, 72202-3591
- Rekruttering
- Arkansas Children's Hospital
-
Ledende efterforsker:
- Michael W. Bishop
-
Kontakt:
- Site Public Contact
- Telefonnummer: 501-364-7373
-
-
California
-
Downey, California, Forenede Stater, 90242
- Rekruttering
- Kaiser Permanente Downey Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 626-564-3455
-
Ledende efterforsker:
- Robert M. Cooper
-
Duarte, California, Forenede Stater, 91010
- Rekruttering
- City of Hope Comprehensive Cancer Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-826-4673
- E-mail: becomingapatient@coh.org
-
Ledende efterforsker:
- Hung C. Tran
-
Loma Linda, California, Forenede Stater, 92354
- Rekruttering
- Loma Linda University Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 909-558-4050
-
Ledende efterforsker:
- Albert Kheradpour
-
Long Beach, California, Forenede Stater, 90806
- Rekruttering
- Miller Children's and Women's Hospital Long Beach
-
Kontakt:
- Site Public Contact
- Telefonnummer: 562-933-5600
-
Ledende efterforsker:
- Jacqueline N. Casillas
-
Los Angeles, California, Forenede Stater, 90027
- Rekruttering
- Children's Hospital Los Angeles
-
Kontakt:
- Site Public Contact
- Telefonnummer: 323-361-4110
-
Ledende efterforsker:
- Araz Marachelian
-
Los Angeles, California, Forenede Stater, 90048
- Rekruttering
- Cedars-Sinai Medical Center
-
Ledende efterforsker:
- Fataneh (Fae) Majlessipour
-
Kontakt:
- Site Public Contact
- Telefonnummer: 310-423-2133
- E-mail: Cancer.trial.info@cshs.org
-
Los Angeles, California, Forenede Stater, 90095
- Rekruttering
- Mattel Children's Hospital UCLA
-
Kontakt:
- Site Public Contact
- Telefonnummer: 310-825-6708
-
Ledende efterforsker:
- Satiro N. De Oliveira
-
Madera, California, Forenede Stater, 93636
- Rekruttering
- Valley Children's Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 559-353-3000
- E-mail: Research@valleychildrens.org
-
Ledende efterforsker:
- Ruetima Titapiwatanakun
-
Oakland, California, Forenede Stater, 94611
- Rekruttering
- Kaiser Permanente-Oakland
-
Kontakt:
- Site Public Contact
- Telefonnummer: 877-642-4691
- E-mail: Kpoct@kp.org
-
Ledende efterforsker:
- Aarati V. Rao
-
Oakland, California, Forenede Stater, 94609
- Rekruttering
- UCSF Benioff Children's Hospital Oakland
-
Ledende efterforsker:
- Jennifer G. Michlitsch
-
Kontakt:
- Site Public Contact
- Telefonnummer: 510-428-3264
- E-mail: PedOncRschOAK@ucsf.edu
-
Orange, California, Forenede Stater, 92868
- Rekruttering
- Children's Hospital of Orange County
-
Kontakt:
- Site Public Contact
- Telefonnummer: 714-509-8646
- E-mail: oncresearch@choc.org
-
Ledende efterforsker:
- Elyssa M. Rubin
-
Palo Alto, California, Forenede Stater, 94304
- Rekruttering
- Lucile Packard Children's Hospital Stanford University
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-694-0012
- E-mail: ccto-office@stanford.edu
-
Ledende efterforsker:
- Jay Michael S. Balagtas
-
Sacramento, California, Forenede Stater, 95817
- Rekruttering
- University of California Davis Comprehensive Cancer Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 916-734-3089
-
Ledende efterforsker:
- Marcio H. Malogolowkin
-
Sacramento, California, Forenede Stater, 95816
- Rekruttering
- Sutter Medical Center Sacramento
-
Kontakt:
- Site Public Contact
- E-mail: clinicalresearch@sutterhealth.org
-
Ledende efterforsker:
- Sandra Baril
-
San Diego, California, Forenede Stater, 92123
- Rekruttering
- Rady Children's Hospital - San Diego
-
Kontakt:
- Site Public Contact
- Telefonnummer: 858-966-5934
-
Ledende efterforsker:
- William D. Roberts
-
San Francisco, California, Forenede Stater, 94158
- Rekruttering
- UCSF Medical Center-Mission Bay
-
Kontakt:
- Site Public Contact
- Telefonnummer: 877-827-3222
- E-mail: cancertrials@ucsf.edu
-
Ledende efterforsker:
- Arun A. Rangaswami
-
-
Colorado
-
Aurora, Colorado, Forenede Stater, 80045
- Rekruttering
- Children's Hospital Colorado
-
Ledende efterforsker:
- Navin R. Pinto
-
Kontakt:
- Site Public Contact
- Telefonnummer: 303-764-5056
- E-mail: josh.b.gordon@nsmtp.kp.org
-
-
Connecticut
-
Hartford, Connecticut, Forenede Stater, 06106
- Rekruttering
- Connecticut Children's Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 860-545-9981
-
Ledende efterforsker:
- Michael S. Isakoff
-
New Haven, Connecticut, Forenede Stater, 06520
- Rekruttering
- Yale University
-
Kontakt:
- Site Public Contact
- Telefonnummer: 203-785-5702
- E-mail: canceranswers@yale.edu
-
Ledende efterforsker:
- Farzana Pashankar
-
-
Delaware
-
Wilmington, Delaware, Forenede Stater, 19803
- Rekruttering
- Alfred I duPont Hospital for Children
-
Kontakt:
- Site Public Contact
- Telefonnummer: 302-651-5572
- E-mail: Allison.bruce@nemours.org
-
Ledende efterforsker:
- Sridhi Patel
-
-
District of Columbia
-
Washington D.C., District of Columbia, Forenede Stater, 20010
- Rekruttering
- Children's National Medical Center
-
Ledende efterforsker:
- Jeffrey S. Dome
-
Kontakt:
- Site Public Contact
- Telefonnummer: 202-476-2800
- E-mail: OncCRC_OnCall@childrensnational.org
-
-
Florida
-
Fort Lauderdale, Florida, Forenede Stater, 33316
- Rekruttering
- Broward Health Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 302-651-5572
- E-mail: Allison.bruce@nemours.org
-
Ledende efterforsker:
- Hector M. Rodriguez-Cortes
-
Fort Myers, Florida, Forenede Stater, 33908
- Rekruttering
- Golisano Children's Hospital of Southwest Florida
-
Kontakt:
- Site Public Contact
- Telefonnummer: 239-343-5333
- E-mail: molly.arnstrom@leehealth.org
-
Ledende efterforsker:
- Emad K. Salman
-
Gainesville, Florida, Forenede Stater, 32610
- Rekruttering
- UF Health Cancer Institute - Gainesville
-
Kontakt:
- Site Public Contact
- Telefonnummer: 352-273-8010
- E-mail: cancer-center@ufl.edu
-
Ledende efterforsker:
- Brian Stover
-
Hollywood, Florida, Forenede Stater, 33021
- Rekruttering
- Memorial Regional Hospital/Joe DiMaggio Children's Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 954-265-1847
- E-mail: OHR@mhs.net
-
Ledende efterforsker:
- Iftikhar Hanif
-
Jacksonville, Florida, Forenede Stater, 32207
- Rekruttering
- Nemours Children's Clinic-Jacksonville
-
Kontakt:
- Site Public Contact
- Telefonnummer: 302-651-5572
- E-mail: Allison.bruce@nemours.org
-
Ledende efterforsker:
- Sridhi Patel
-
Miami, Florida, Forenede Stater, 33155
- Rekruttering
- Nicklaus Children's Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 888-624-2778
-
Ledende efterforsker:
- Ziad A. Khatib
-
Miami, Florida, Forenede Stater, 33136
- Rekruttering
- University of Miami Miller School of Medicine-Sylvester Cancer Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 305-243-2647
-
Ledende efterforsker:
- Meghan McCormick
-
Orlando, Florida, Forenede Stater, 32806
- Rekruttering
- Arnold Palmer Hospital for Children
-
Kontakt:
- Site Public Contact
- Telefonnummer: 321-841-5357
- E-mail: Jennifer.spinelli@orlandohealth.com
-
Ledende efterforsker:
- Zhongbo Hu
-
Orlando, Florida, Forenede Stater, 32827
- Rekruttering
- Nemours Children's Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 302-651-5572
- E-mail: Allison.bruce@nemours.org
-
Ledende efterforsker:
- Sridhi Patel
-
Orlando, Florida, Forenede Stater, 32803
- Rekruttering
- AdventHealth Orlando
-
Kontakt:
- Site Public Contact
- Telefonnummer: 407-303-2090
- E-mail: FH.Cancer.Research@flhosp.org
-
Ledende efterforsker:
- Fouad M. Hajjar
-
St. Petersburg, Florida, Forenede Stater, 33701
- Rekruttering
- Johns Hopkins All Children's Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 727-767-4784
- E-mail: Ashley.Repp@jhmi.edu
-
Ledende efterforsker:
- Jennifer B. Dean
-
West Palm Beach, Florida, Forenede Stater, 33407
- Rekruttering
- Saint Mary's Medical Center
-
Ledende efterforsker:
- Matthew D. Ramirez
-
Kontakt:
- Site Public Contact
- Telefonnummer: 561-822-4745
-
-
Georgia
-
Atlanta, Georgia, Forenede Stater, 30329
- Rekruttering
- Children's Healthcare of Atlanta - Arthur M Blank Hospital
-
Ledende efterforsker:
- William T. Cash
-
Kontakt:
- Site Public Contact
- Telefonnummer: 404-785-0232
- E-mail: Olivia.Floyd@choa.org
-
Savannah, Georgia, Forenede Stater, 31404
- Rekruttering
- Memorial Health University Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 912-350-7887
- E-mail: Lorraine.OHara@hcahealthcare.com
-
Ledende efterforsker:
- James N. Yarnall
-
-
Hawaii
-
Honolulu, Hawaii, Forenede Stater, 96826
- Rekruttering
- Kapiolani Medical Center for Women and Children
-
Kontakt:
- Site Public Contact
- Telefonnummer: 808-983-6090
-
Ledende efterforsker:
- Wade T. Kyono
-
-
Illinois
-
Chicago, Illinois, Forenede Stater, 60611
- Rekruttering
- Lurie Children's Hospital-Chicago
-
Kontakt:
- Site Public Contact
- Telefonnummer: 773-880-4562
-
Ledende efterforsker:
- Elizabeth A. Sokol
-
Chicago, Illinois, Forenede Stater, 60637
- Rekruttering
- University of Chicago Comprehensive Cancer Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 773-702-8222
- E-mail: cancerclinicaltrials@bsd.uchicago.edu
-
Ledende efterforsker:
- Ami V. Desai
-
Chicago, Illinois, Forenede Stater, 60612
- Rekruttering
- University of Illinois
-
Kontakt:
- Site Public Contact
- Telefonnummer: 312-355-3046
-
Ledende efterforsker:
- Dipti S. Dighe
-
Oak Lawn, Illinois, Forenede Stater, 60453
- Rekruttering
- Advocate Children's Hospital-Oak Lawn
-
Kontakt:
- Site Public Contact
- Telefonnummer: 847-723-7570
-
Ledende efterforsker:
- Rebecca E. McFall
-
Park Ridge, Illinois, Forenede Stater, 60068
- Rekruttering
- Advocate Children's Hospital-Park Ridge
-
Kontakt:
- Site Public Contact
- E-mail: helpdesk@childrensoncologygroup.org
-
Ledende efterforsker:
- Rebecca E. McFall
-
Peoria, Illinois, Forenede Stater, 61637
- Rekruttering
- OSF Children's Hospital of Illinois
-
Ledende efterforsker:
- Prerna Kumar
-
Kontakt:
- Site Public Contact
- Telefonnummer: 309-624-4945
- E-mail: ChildrensHospitalofIllinois@osfhealthcare.org
-
Springfield, Illinois, Forenede Stater, 62702
- Rekruttering
- Southern Illinois University School of Medicine
-
Kontakt:
- Site Public Contact
- Telefonnummer: 217-545-7929
-
Ledende efterforsker:
- Gregory P. Brandt
-
-
Indiana
-
Indianapolis, Indiana, Forenede Stater, 46202
- Rekruttering
- Riley Hospital for Children
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-248-1199
-
Ledende efterforsker:
- Marissa Just
-
Indianapolis, Indiana, Forenede Stater, 46260
- Rekruttering
- Ascension Saint Vincent Indianapolis Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 317-338-2194
- E-mail: research@stvincent.org
-
Ledende efterforsker:
- Bassem I. Razzouk
-
-
Iowa
-
Des Moines, Iowa, Forenede Stater, 50309
- Rekruttering
- Blank Children's Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 515-241-8912
- E-mail: samantha.mallory@unitypoint.org
-
Ledende efterforsker:
- Samantha L. Mallory
-
Iowa City, Iowa, Forenede Stater, 52242
- Rekruttering
- University of Iowa/Holden Comprehensive Cancer Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-237-1225
-
Ledende efterforsker:
- Andrew P. Groves
-
-
Kansas
-
Wichita, Kansas, Forenede Stater, 67214
- Rekruttering
- Wesley Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 316-962-7802
- E-mail: WesleyResearch@wesleymc.com
-
Ledende efterforsker:
- Nathan S. Hall
-
-
Kentucky
-
Lexington, Kentucky, Forenede Stater, 40536
- Rekruttering
- University of Kentucky/Markey Cancer Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 859-257-3379
-
Ledende efterforsker:
- James T. Badgett
-
Louisville, Kentucky, Forenede Stater, 40202
- Rekruttering
- Norton Children's Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 502-629-5500
- E-mail: CancerResource@nortonhealthcare.org
-
Ledende efterforsker:
- Michael J. Ferguson
-
-
Louisiana
-
New Orleans, Louisiana, Forenede Stater, 70118
- Rekruttering
- Children's Hospital New Orleans
-
Ledende efterforsker:
- Maria C. Velez-Yanguas
-
Kontakt:
- Site Public Contact
- Telefonnummer: 504-894-5377
-
-
Maine
-
Bangor, Maine, Forenede Stater, 04401
- Rekruttering
- Eastern Maine Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 207-973-4274
-
Ledende efterforsker:
- Daniel L. Callaway
-
Scarborough, Maine, Forenede Stater, 04074
- Rekruttering
- Maine Children's Cancer Program
-
Ledende efterforsker:
- Sei-Gyung K. Sze
-
Kontakt:
- Site Public Contact
- Telefonnummer: 207-396-8670
- E-mail: clinicalresearch@mainehealth.org
-
-
Maryland
-
Baltimore, Maryland, Forenede Stater, 21287
- Rekruttering
- Johns Hopkins University/Sidney Kimmel Cancer Center
-
Ledende efterforsker:
- Allen R. Chen
-
Kontakt:
- Site Public Contact
- Telefonnummer: 410-955-8804
- E-mail: jhcccro@jhmi.edu
-
Baltimore, Maryland, Forenede Stater, 21215
- Rekruttering
- Sinai Hospital of Baltimore
-
Ledende efterforsker:
- Jason M. Fixler
-
Kontakt:
- Site Public Contact
- Telefonnummer: 410-601-9083
-
Baltimore, Maryland, Forenede Stater, 21201
- Rekruttering
- University of Maryland/Greenebaum Cancer Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-888-8823
-
Ledende efterforsker:
- Teresa A. York
-
Bethesda, Maryland, Forenede Stater, 20889-5600
- Rekruttering
- Walter Reed National Military Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 301-319-2100
-
Ledende efterforsker:
- Kip R. Hartman
-
-
Massachusetts
-
Boston, Massachusetts, Forenede Stater, 02114
- Rekruttering
- Massachusetts General Hospital Cancer Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 877-726-5130
-
Ledende efterforsker:
- Lauren H. Boal
-
Boston, Massachusetts, Forenede Stater, 02215
- Rekruttering
- Dana-Farber Cancer Institute
-
Kontakt:
- Site Public Contact
- Telefonnummer: 877-442-3324
-
Ledende efterforsker:
- Suzanne Shusterman
-
-
Michigan
-
Ann Arbor, Michigan, Forenede Stater, 48109
- Rekruttering
- C S Mott Children's Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-865-1125
-
Ledende efterforsker:
- Rajen Mody
-
Detroit, Michigan, Forenede Stater, 48201
- Suspenderet
- Children's Hospital of Michigan
-
Grand Rapids, Michigan, Forenede Stater, 49503
- Rekruttering
- Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 616-391-1230
- E-mail: crcwm-regulatory@crcwm.org
-
Ledende efterforsker:
- Kathleen Y. Butler
-
Kalamazoo, Michigan, Forenede Stater, 49007
- Rekruttering
- Bronson Methodist Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 616-391-1230
- E-mail: crcwm-regulatory@crcwm.org
-
Ledende efterforsker:
- Kathleen Y. Butler
-
Royal Oak, Michigan, Forenede Stater, 48073
- Rekruttering
- Corewell Health Children's
-
Kontakt:
- Site Public Contact
- Telefonnummer: 248-551-7695
-
Ledende efterforsker:
- Marie V. Nelson
-
-
Minnesota
-
Minneapolis, Minnesota, Forenede Stater, 55404
- Rekruttering
- Children's Hospitals and Clinics of Minnesota - Minneapolis
-
Ledende efterforsker:
- Michael K. Richards
-
Kontakt:
- Site Public Contact
- Telefonnummer: 612-813-5913
- E-mail: pauline.mitby@childrensmn.org
-
Minneapolis, Minnesota, Forenede Stater, 55455
- Rekruttering
- University of Minnesota/Masonic Cancer Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 612-624-2620
-
Ledende efterforsker:
- Robin L. Williams
-
Rochester, Minnesota, Forenede Stater, 55905
- Rekruttering
- Mayo Clinic in Rochester
-
Kontakt:
- Site Public Contact
- Telefonnummer: 855-776-0015
-
Ledende efterforsker:
- Peter Schoettler
-
-
Mississippi
-
Jackson, Mississippi, Forenede Stater, 39216
- Rekruttering
- University of Mississippi Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 601-815-6700
-
Ledende efterforsker:
- Amanda Strobel
-
-
Missouri
-
Columbia, Missouri, Forenede Stater, 65212
- Rekruttering
- University of Missouri Children's Hospital
-
Ledende efterforsker:
- Barbara A. Gruner
-
Kontakt:
- Site Public Contact
- Telefonnummer: 573-882-1960
- E-mail: snwq62@health.missouri.edu
-
Kansas City, Missouri, Forenede Stater, 64108
- Rekruttering
- Children's Mercy Hospitals and Clinics
-
Ledende efterforsker:
- Keith J. August
-
Kontakt:
- Site Public Contact
- Telefonnummer: 816-302-6808
- E-mail: COGResearchGroup@cmh.edu
-
St Louis, Missouri, Forenede Stater, 63110
- Rekruttering
- Washington University School of Medicine
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-600-3606
- E-mail: info@siteman.wustl.edu
-
Ledende efterforsker:
- Frederick S. Huang
-
St Louis, Missouri, Forenede Stater, 63141
- Rekruttering
- Mercy Hospital Saint Louis
-
Kontakt:
- Site Public Contact
- Telefonnummer: 314-251-7066
-
Ledende efterforsker:
- Robin D. Hanson
-
-
Nebraska
-
Omaha, Nebraska, Forenede Stater, 68114
- Rekruttering
- Children's Hospital and Medical Center of Omaha
-
Kontakt:
- Site Public Contact
- Telefonnummer: 402-955-3949
-
Ledende efterforsker:
- Jill C. Beck
-
Omaha, Nebraska, Forenede Stater, 68198
- Rekruttering
- University of Nebraska Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 402-559-6941
- E-mail: unmcrsa@unmc.edu
-
Ledende efterforsker:
- Jill C. Beck
-
-
Nevada
-
Las Vegas, Nevada, Forenede Stater, 89135
- Rekruttering
- Alliance for Childhood Diseases/Cure 4 the Kids Foundation
-
Kontakt:
- Site Public Contact
- Telefonnummer: 702-384-0013
- E-mail: research@sncrf.org
-
Ledende efterforsker:
- Joseph L. Lasky
-
-
New Hampshire
-
Lebanon, New Hampshire, Forenede Stater, 03756
- Rekruttering
- Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center
-
Ledende efterforsker:
- Angela Ricci
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-639-6918
- E-mail: cancer.research.nurse@dartmouth.edu
-
-
New Jersey
-
Hackensack, New Jersey, Forenede Stater, 07601
- Rekruttering
- Hackensack University Medical Center
-
Ledende efterforsker:
- Katharine Offer
-
Kontakt:
- Site Public Contact
- Telefonnummer: 551-996-2897
-
Morristown, New Jersey, Forenede Stater, 07960
- Rekruttering
- Morristown Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 973-971-5900
-
Ledende efterforsker:
- Kathryn L. Laurie
-
New Brunswick, New Jersey, Forenede Stater, 08901
- Rekruttering
- Saint Peter's University Hospital
-
Ledende efterforsker:
- Nibal A. Zaghloul
-
Kontakt:
- Site Public Contact
- Telefonnummer: 732-745-8600
- E-mail: officeofresearch@saintpetersuh.com
-
New Brunswick, New Jersey, Forenede Stater, 08903
- Rekruttering
- Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 732-235-8675
-
Ledende efterforsker:
- Nehal S. Parikh
-
Newark, New Jersey, Forenede Stater, 07112
- Rekruttering
- Newark Beth Israel Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 973-926-7230
- E-mail: Christine.Kosmides@rwjbh.org
-
Ledende efterforsker:
- Teena Bhatla
-
Paterson, New Jersey, Forenede Stater, 07503
- Rekruttering
- Saint Joseph's Regional Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 973-754-2207
- E-mail: HallL@sjhmc.org
-
Ledende efterforsker:
- Alissa Kahn
-
-
New Mexico
-
Albuquerque, New Mexico, Forenede Stater, 87106
- Suspenderet
- University of New Mexico Cancer Center
-
-
New York
-
Albany, New York, Forenede Stater, 12208
- Rekruttering
- Albany Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 518-262-5513
-
Ledende efterforsker:
- Lauren R. Weintraub
-
Buffalo, New York, Forenede Stater, 14263
- Rekruttering
- Roswell Park Cancer Institute
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-767-9355
- E-mail: askroswell@roswellpark.org
-
Ledende efterforsker:
- Clare J. Twist
-
Mineola, New York, Forenede Stater, 11501
- Rekruttering
- NYU Langone Hospital - Long Island
-
Kontakt:
- Site Public Contact
- Telefonnummer: 212-263-4432
- E-mail: cancertrials@nyulangone.org
-
Ledende efterforsker:
- Chana L. Glasser
-
New Hyde Park, New York, Forenede Stater, 11040
- Rekruttering
- The Steven and Alexandra Cohen Children's Medical Center of New York
-
Kontakt:
- Site Public Contact
- Telefonnummer: 718-470-3460
-
Ledende efterforsker:
- Julie I. Krystal
-
New York, New York, Forenede Stater, 10032
- Rekruttering
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
-
Ledende efterforsker:
- Nobuko Hijiya
-
Kontakt:
- Site Public Contact
- Telefonnummer: 212-342-5162
- E-mail: cancerclinicaltrials@cumc.columbia.edu
-
New York, New York, Forenede Stater, 10016
- Rekruttering
- Laura and Isaac Perlmutter Cancer Center at NYU Langone
-
Ledende efterforsker:
- Elizabeth A. Raetz
-
Kontakt:
- Site Public Contact
- E-mail: CancerTrials@nyulangone.org
-
Rochester, New York, Forenede Stater, 14642
- Rekruttering
- University of Rochester
-
Kontakt:
- Site Public Contact
- Telefonnummer: 585-275-5830
-
Ledende efterforsker:
- Rafi R. Kazi
-
Syracuse, New York, Forenede Stater, 13210
- Rekruttering
- State University of New York Upstate Medical University
-
Kontakt:
- Site Public Contact
- Telefonnummer: 315-464-5476
-
Ledende efterforsker:
- Melanie A. Comito
-
The Bronx, New York, Forenede Stater, 10467
- Rekruttering
- Montefiore Medical Center - Moses Campus
-
Kontakt:
- Site Public Contact
- Telefonnummer: 718-379-6866
- E-mail: eskwak@montefiore.org
-
Ledende efterforsker:
- Alice Lee
-
Valhalla, New York, Forenede Stater, 10595
- Rekruttering
- New York Medical College
-
Kontakt:
- Site Public Contact
- Telefonnummer: 914-594-3794
-
Ledende efterforsker:
- Andrew J. Bellantoni
-
-
North Carolina
-
Asheville, North Carolina, Forenede Stater, 28801
- Rekruttering
- Mission Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 828-213-7055
- E-mail: NCDV.ResearchRegulatory@HCAHealthcare.com
-
Ledende efterforsker:
- Douglas J. Scothorn
-
Chapel Hill, North Carolina, Forenede Stater, 27599
- Rekruttering
- UNC Lineberger Comprehensive Cancer Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 877-668-0683
- E-mail: cancerclinicaltrials@med.unc.edu
-
Ledende efterforsker:
- Thomas B. Alexander
-
Charlotte, North Carolina, Forenede Stater, 28203
- Rekruttering
- Carolinas Medical Center/Levine Cancer Institute
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-804-9376
-
Ledende efterforsker:
- Joel A. Kaplan
-
Charlotte, North Carolina, Forenede Stater, 28204
- Rekruttering
- Novant Health Presbyterian Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 980-201-6360
- E-mail: kashah@novanthealth.org
-
Ledende efterforsker:
- Holly Edington
-
Durham, North Carolina, Forenede Stater, 27710
- Rekruttering
- Duke University Medical Center
-
Ledende efterforsker:
- Jessica M. Sun
-
Kontakt:
- Site Public Contact
- Telefonnummer: 888-275-3853
-
Greenville, North Carolina, Forenede Stater, 27834
- Rekruttering
- East Carolina University
-
Kontakt:
- Site Public Contact
- Telefonnummer: 252-744-1015
- E-mail: eubankss@ecu.edu
-
Ledende efterforsker:
- Andrea R. Whitfield
-
Winston-Salem, North Carolina, Forenede Stater, 27157
- Rekruttering
- Wake Forest University Health Sciences
-
Kontakt:
- Site Public Contact
- Telefonnummer: 336-713-6771
-
Ledende efterforsker:
- Sarah Supples
-
-
North Dakota
-
Fargo, North Dakota, Forenede Stater, 58122
- Rekruttering
- Sanford Broadway Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 701-323-5760
- E-mail: OncologyClinicalTrialsFargo@sanfordhealth.org
-
Ledende efterforsker:
- Samuel J. Milanovich
-
-
Ohio
-
Akron, Ohio, Forenede Stater, 44308
- Rekruttering
- Children's Hospital Medical Center of Akron
-
Kontakt:
- Site Public Contact
- Telefonnummer: 330-543-3193
-
Ledende efterforsker:
- Lauren R. Draper
-
Cincinnati, Ohio, Forenede Stater, 45229
- Rekruttering
- Cincinnati Children's Hospital Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 513-636-2799
- E-mail: cancer@cchmc.org
-
Ledende efterforsker:
- Katherine M. Somers
-
Cleveland, Ohio, Forenede Stater, 44195
- Rekruttering
- Cleveland Clinic Foundation
-
Kontakt:
- Site Public Contact
- Telefonnummer: 866-223-8100
- E-mail: TaussigResearch@ccf.org
-
Ledende efterforsker:
- Matteo M. Trucco
-
Cleveland, Ohio, Forenede Stater, 44106
- Rekruttering
- Rainbow Babies and Childrens Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 216-844-5437
-
Ledende efterforsker:
- Duncan S. Stearns
-
Columbus, Ohio, Forenede Stater, 43205
- Rekruttering
- Nationwide Children's Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 614-722-6039
- E-mail: Melinda.Triplet@nationwidechildrens.org
-
Ledende efterforsker:
- Mark A. Ranalli
-
Dayton, Ohio, Forenede Stater, 45404
- Rekruttering
- Dayton Children's Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-228-4055
-
Ledende efterforsker:
- Jordan M. Wright
-
Toledo, Ohio, Forenede Stater, 43606
- Rekruttering
- ProMedica Toledo Hospital/Russell J Ebeid Children's Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 419-824-1842
- E-mail: PCIOncResearch@promedica.org
-
Ledende efterforsker:
- Jamie L. Dargart
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Forenede Stater, 73104
- Rekruttering
- University of Oklahoma Health Sciences Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 405-271-8777
- E-mail: ou-clinical-trials@ouhsc.edu
-
Ledende efterforsker:
- Rene Y. McNall-Knapp
-
Tulsa, Oklahoma, Forenede Stater, 74136
- Rekruttering
- Saint Francis Children's Hospital
-
Ledende efterforsker:
- Jill A. Salo
-
Kontakt:
- Site Public Contact
- Telefonnummer: 918-502-6720
-
-
Oregon
-
Portland, Oregon, Forenede Stater, 97227
- Rekruttering
- Legacy Emanuel Children's Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 503-413-2560
-
Ledende efterforsker:
- Jason M. Glover
-
Portland, Oregon, Forenede Stater, 97239
- Rekruttering
- Oregon Health and Science University
-
Kontakt:
- Site Public Contact
- Telefonnummer: 503-494-1080
- E-mail: trials@ohsu.edu
-
Ledende efterforsker:
- Susan J. Lindemulder
-
-
Pennsylvania
-
Allentown, Pennsylvania, Forenede Stater, 18103
- Rekruttering
- Lehigh Valley Hospital-Cedar Crest
-
Kontakt:
- Site Public Contact
- Telefonnummer: 610-402-9543
- E-mail: Morgan_M.Horton@lvhn.org
-
Ledende efterforsker:
- Jacob A. Troutman
-
Danville, Pennsylvania, Forenede Stater, 17822
- Rekruttering
- Geisinger Medical Center
-
Ledende efterforsker:
- Jagadeesh Ramdas
-
Kontakt:
- Site Public Contact
- Telefonnummer: 570-271-5251
- E-mail: cancerresearch@geisinger.edu
-
Philadelphia, Pennsylvania, Forenede Stater, 19104
- Rekruttering
- Children's Hospital of Philadelphia
-
Ledende efterforsker:
- Rochelle Bagatell
-
Kontakt:
- Site Public Contact
- Telefonnummer: 267-425-5544
- E-mail: CancerTrials@email.chop.edu
-
Philadelphia, Pennsylvania, Forenede Stater, 19134
- Rekruttering
- Saint Christopher's Hospital for Children
-
Kontakt:
- Site Public Contact
- Telefonnummer: 215-427-8991
-
Ledende efterforsker:
- Gregory E. Halligan
-
Pittsburgh, Pennsylvania, Forenede Stater, 15224
- Rekruttering
- Children's Hospital of Pittsburgh of UPMC
-
Kontakt:
- Site Public Contact
- Telefonnummer: 412-692-8570
- E-mail: jean.tersak@chp.edu
-
Ledende efterforsker:
- Jean M. Tersak
-
-
Rhode Island
-
Providence, Rhode Island, Forenede Stater, 02903
- Rekruttering
- Rhode Island Hospital
-
Ledende efterforsker:
- Bradley DeNardo
-
Kontakt:
- Site Public Contact
- Telefonnummer: 401-444-1488
-
-
South Carolina
-
Charleston, South Carolina, Forenede Stater, 29425
- Rekruttering
- Medical University of South Carolina
-
Kontakt:
- Site Public Contact
- Telefonnummer: 843-792-9321
- E-mail: hcc-clinical-trials@musc.edu
-
Ledende efterforsker:
- Jacqueline M. Kraveka
-
Columbia, South Carolina, Forenede Stater, 29203
- Rekruttering
- Prisma Health Richland Hospital
-
Ledende efterforsker:
- Stuart L. Cramer
-
Kontakt:
- Site Public Contact
- Telefonnummer: 864-522-4317
- E-mail: Kim.Williams3@prismahealth.org
-
Greenville, South Carolina, Forenede Stater, 29605
- Rekruttering
- BI-LO Charities Children's Cancer Center
-
Ledende efterforsker:
- Aniket Saha
-
Kontakt:
- Site Public Contact
- Telefonnummer: 864-522-4317
- E-mail: Kim.Williams3@prismahealth.org
-
-
South Dakota
-
Sioux Falls, South Dakota, Forenede Stater, 57117-5134
- Rekruttering
- Sanford USD Medical Center - Sioux Falls
-
Kontakt:
- Site Public Contact
- Telefonnummer: 605-312-3320
- E-mail: OncologyClinicalTrialsSF@SanfordHealth.org
-
Ledende efterforsker:
- Jordan Fritch-Hanson
-
-
Tennessee
-
Knoxville, Tennessee, Forenede Stater, 37916
- Rekruttering
- East Tennessee Childrens Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 865-541-8266
-
Ledende efterforsker:
- Susan E. Spiller
-
Memphis, Tennessee, Forenede Stater, 38105
- Rekruttering
- Saint Jude Children's Research Hospital
-
Ledende efterforsker:
- Sara M. Federico
-
Kontakt:
- Site Public Contact
- Telefonnummer: 888-226-4343
- E-mail: referralinfo@stjude.org
-
Nashville, Tennessee, Forenede Stater, 37232
- Rekruttering
- Vanderbilt University/Ingram Cancer Center
-
Ledende efterforsker:
- Daniel J. Benedetti
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-811-8480
-
Nashville, Tennessee, Forenede Stater, 37203
- Rekruttering
- The Children's Hospital at TriStar Centennial
-
Kontakt:
- Site Public Contact
- Telefonnummer: 615-342-1919
-
Ledende efterforsker:
- Clinton M. Carroll
-
-
Texas
-
Austin, Texas, Forenede Stater, 78723
- Rekruttering
- Dell Children's Medical Center of Central Texas
-
Kontakt:
- Site Public Contact
- Telefonnummer: 512-628-1902
- E-mail: TXAUS-DL-SFCHemonc.research@ascension.org
-
Ledende efterforsker:
- Shannon M. Cohn
-
Corpus Christi, Texas, Forenede Stater, 78411
- Rekruttering
- Driscoll Children's Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 361-694-5311
- E-mail: Crystal.DeLosSantos@dchstx.org
-
Ledende efterforsker:
- Nkechi I. Mba
-
Dallas, Texas, Forenede Stater, 75390
- Rekruttering
- UT Southwestern/Simmons Cancer Center-Dallas
-
Ledende efterforsker:
- Tanya C. Watt
-
Kontakt:
- Site Public Contact
- Telefonnummer: 214-648-7097
- E-mail: canceranswerline@UTSouthwestern.edu
-
Dallas, Texas, Forenede Stater, 75230
- Rekruttering
- Medical City Dallas Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 972-566-5588
-
Ledende efterforsker:
- Maurizio L. Ghisoli
-
El Paso, Texas, Forenede Stater, 79905
- Rekruttering
- El Paso Children's Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 915-298-5444
- E-mail: ranjan.bista@ttuhsc.edu
-
Ledende efterforsker:
- Benjamin Carcamo
-
Fort Worth, Texas, Forenede Stater, 76104
- Rekruttering
- Cook Children's Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 682-885-2103
- E-mail: CookChildrensResearch@cookchildrens.org
-
Ledende efterforsker:
- Chelsee Greer
-
Houston, Texas, Forenede Stater, 77030
- Rekruttering
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 713-798-1354
- E-mail: burton@bcm.edu
-
Ledende efterforsker:
- Jennifer H. Foster
-
Houston, Texas, Forenede Stater, 77030
- Rekruttering
- UT MD Anderson Cancer Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 866-632-6789
- E-mail: askmdanderson@mdanderson.org
-
Ledende efterforsker:
- Najat C. Daw
-
Lubbock, Texas, Forenede Stater, 79410
- Rekruttering
- Covenant Children's Hospital
-
Ledende efterforsker:
- Kishor M. Bhende
-
Kontakt:
- Site Public Contact
- Telefonnummer: 806-725-8657
- E-mail: mbisbee@providence.org
-
Lubbock, Texas, Forenede Stater, 79415
- Rekruttering
- UMC Cancer Center / UMC Health System
-
Kontakt:
- Site Public Contact
- Telefonnummer: 806-775-8590
-
Ledende efterforsker:
- Erin K. Barr
-
San Antonio, Texas, Forenede Stater, 78207
- Rekruttering
- Children's Hospital of San Antonio
-
Kontakt:
- Site Public Contact
- Telefonnummer: 210-704-2894
- E-mail: bridget.medina@christushealth.org
-
Ledende efterforsker:
- Julie Voeller
-
San Antonio, Texas, Forenede Stater, 78229
- Rekruttering
- University of Texas Health Science Center at San Antonio
-
Kontakt:
- Site Public Contact
- Telefonnummer: 210-450-3800
- E-mail: phoresearchoffice@uthscsa.edu
-
Ledende efterforsker:
- Aaron J. Sugalski
-
San Antonio, Texas, Forenede Stater, 78229
- Rekruttering
- Methodist Children's Hospital of South Texas
-
Kontakt:
- Site Public Contact
- Telefonnummer: 210-575-6240
- E-mail: Vinod.GidvaniDiaz@hcahealthcare.com
-
Ledende efterforsker:
- Jose M. Esquilin
-
-
Utah
-
Salt Lake City, Utah, Forenede Stater, 84113
- Rekruttering
- Primary Children's Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 801-585-5270
-
Ledende efterforsker:
- Leonora R. Slatnick
-
-
Vermont
-
Burlington, Vermont, Forenede Stater, 05405
- Rekruttering
- University of Vermont and State Agricultural College
-
Kontakt:
- Site Public Contact
- Telefonnummer: 802-656-8990
- E-mail: rpo@uvm.edu
-
Ledende efterforsker:
- Jessica L. Heath
-
-
Virginia
-
Charlottesville, Virginia, Forenede Stater, 22908
- Rekruttering
- University of Virginia Cancer Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 434-243-6303
- E-mail: uvacancertrials@hscmail.mcc.virginia.edu
-
Ledende efterforsker:
- Brian C. Belyea
-
Portsmouth, Virginia, Forenede Stater, 23708-2197
- Rekruttering
- Naval Medical Center - Portsmouth
-
Kontakt:
- Site Public Contact
- Telefonnummer: 757-953-5939
-
Ledende efterforsker:
- Karin Brockman
-
-
Washington
-
Seattle, Washington, Forenede Stater, 98105
- Rekruttering
- Seattle Children's Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 866-987-2000
-
Ledende efterforsker:
- Sarah E. Leary
-
Spokane, Washington, Forenede Stater, 99204
- Rekruttering
- Providence Sacred Heart Medical Center and Children's Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-228-6618
- E-mail: HopeBeginsHere@providence.org
-
Ledende efterforsker:
- Judy L. Felgenhauer
-
Tacoma, Washington, Forenede Stater, 98405
- Rekruttering
- Mary Bridge Children's Hospital and Health Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 253-403-1461
- E-mail: research@multicare.org
-
Ledende efterforsker:
- Robert G. Irwin
-
-
West Virginia
-
Huntington, West Virginia, Forenede Stater, 25701
- Rekruttering
- Edwards Comprehensive Cancer Center
-
Ledende efterforsker:
- Mark A. Ranalli
-
Kontakt:
- Site Public Contact
- Telefonnummer: 304-399-6566
- E-mail: Christina.Cole@chhi.org
-
Morgantown, West Virginia, Forenede Stater, 26506
- Rekruttering
- West Virginia University Healthcare
-
Kontakt:
- Site Public Contact
- Telefonnummer: 304-293-7374
- E-mail: cancertrialsinfo@hsc.wvu.edu
-
Ledende efterforsker:
- Ashley E. Meyer
-
-
Wisconsin
-
Green Bay, Wisconsin, Forenede Stater, 54301
- Suspenderet
- Saint Vincent Hospital Cancer Center Green Bay
-
Madison, Wisconsin, Forenede Stater, 53792
- Rekruttering
- University of Wisconsin Carbone Cancer Center - University Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-622-8922
- E-mail: clinicaltrials@cancer.wisc.edu
-
Ledende efterforsker:
- Margo L. Hoover-Regan
-
Marshfield, Wisconsin, Forenede Stater, 54449
- Rekruttering
- Marshfield Medical Center-Marshfield
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-782-8581
- E-mail: oncology.clinical.trials@marshfieldresearch.org
-
Ledende efterforsker:
- Michelle A. Manalang
-
Milwaukee, Wisconsin, Forenede Stater, 53226
- Rekruttering
- Children's Hospital of Wisconsin
-
Ledende efterforsker:
- Angela Steineck
-
Kontakt:
- Site Public Contact
- Telefonnummer: 414-955-4727
- E-mail: MACCCTO@mcw.edu
-
-
-
-
Auckland
-
Grafton, Auckland, New Zealand, 1145
- Rekruttering
- Starship Children's Hospital
-
Ledende efterforsker:
- Andrew C. Wood
-
Kontakt:
- Site Public Contact
- Telefonnummer: 0800 728 436
-
-
-
-
-
San Juan, Puerto Rico, 00926
- Rekruttering
- University Pediatric Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 787-474-0333
-
Ledende efterforsker:
- Maria E. Echevarria
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
-
Patients must be enrolled on APEC14B1 and have consented to testing through the Molecular Characterization Initiative (MCI), prior to enrollment on ANBL2131
-
≤ 30 years at the time of initial diagnosis with high-risk disease
-
* Must have a diagnosis of neuroblastoma (NBL) or ganglioneuroblastoma (nodular) verified by tumor pathology analysis or demonstration of clumps of tumor cells in bone marrow with elevated urinary catecholamines
-
Newly diagnosed, high risk neuroblastoma (HRNBL) defined as one of the following:
- Any age with International Neuroblastoma Risk Group (INRG) Stage L2, MS, or M and MYCN amplification
- Age ≥ 547 days and INRG stage M regardless of biologic features (clinical MYCN testing not required prior to enrollment)
- Any age initially diagnosed with INRG Stage L1 MYCN amplified NBL who have progressed to stage M without systemic chemotherapy
- Age ≥ 547 days of age initially diagnosed with INRG Stage L1, L2, or MS who have progressed to stage M without systemic chemotherapy (clinical MYCN testing not required prior to enrollment)
-
-
Patients must have a body surface area (BSA) ≥ 0.25 m^2
-
No prior anti-cancer therapy except as outlined below:
- Patients initially recognized to have high-risk disease treated with topotecan/cyclophosphamide initiated on an emergent basis and within allowed timing, and with consent
- Patients observed or treated with a single cycle of chemotherapy per a low or intermediate risk neuroblastoma regimen (e.g., as per ANBL0531, ANBL1232 or similar) for what initially appeared to be non-high-risk disease but subsequently found to meet the criteria
- Patients who received localized emergency radiation to sites of life threatening or function-threatening disease prior to or immediately after establishment of the definitive diagnosis
-
Human immunodeficiency virus (HIV) -infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial
-
A serum creatinine based on age/sex as follows:
-
1 month to < 6 months: Male 0.4 mg/dL and female 0.4mg/dL
-
6 months to < 1 year: Male 0.5 mg/dL and female 0.5 mg/dL
-
1 to < 2 years: Male 0.6 mg/dL and female 0.6 mg/dL
-
2 to < 6 years: Male 0.8 mg/dL and female 0.8 mg/dL
-
6 to < 10 years: Male 1 mg/dL and female 1 mg/dL
-
10 to < 13 years: Male 1.2 mg/dL and female 1.2 mg/dL
-
13 to < 16 years: Male 1.5 mg/dL and female 1.4 mg/dL
-
≥ 16 years: Male 1.7 mg/dL and female 1.4 mg/dL
- The threshold creatinine values were derived from the Schwartz formula for estimating glomerular filtration rate (GFR) utilizing child length and stature data published by the Centers for Disease Control (CDC)
-
or a 24-hour urine creatinine clearance ≥ 70 mL/min/1.73 m^2 or
-
or a GFR ≥ 70 mL/min/1.73 m^2. GFR must be performed using direct measurement with a nuclear blood sampling method or direct small molecule clearance method (iothalamate or other molecule per institutional standard)
- Note: Estimated GFR (eGFR) from serum creatinine, cystatin C or other estimates are not acceptable for determining eligibility
-
-
Total bilirubin ≤ 1.5 x upper limit of normal (ULN) for age
-
Serum glutamic pyruvic transaminase (SGPT) (Alanine aminotransferase [ALT]) ≤ 10 x ULN*
- Note: For the purpose of this study, the ULN for SGPT (ALT) has been set to the value of 45 U/L
-
* Shortening fraction of ≥ 27% by echocardiogram, or
- Ejection fraction of ≥ 50% by echocardiogram or radionuclide angiogram
-
Ability to tolerate Peripheral Blood Stem Cell (PBSC) collection:
No known contraindication to PBSC collection. Examples of contraindications might be a weight or size less than the collecting institution finds feasible, or a physical condition that would limit the ability of the child to undergo apheresis catheter placement (if necessary) and/or the apheresis procedure
Exclusion Criteria:
- Patients who are 365-546 days of age with INRG Stage M and MYCN non-amplified NBL, irrespective of additional biologic features
- Patients ≥ 547 days of age with INRG Stage L2, MYCN non-amplified NBL, regardless of additional biologic features
- Patients with known bone marrow failure syndromes
- Patients on chronic immunosuppressive medications (e.g., tacrolimus, cyclosporine, corticosteroids) for reasons other than prevention/treatment of allergic reactions and adrenal replacement therapy are not eligible. Topical and inhaled corticosteroids are acceptable
- Patients with a primary immunodeficiency syndrome who require ongoing immune globulin replacement therapy
- Female patients who are pregnant since fetal toxicities and teratogenic effects have been noted for several of the study drugs. A pregnancy test is required prior to enrollment for female patients of childbearing potential
- Lactating females who plan to breastfeed their infants
- Sexually active patients of reproductive potential who have not agreed to use an effective contraceptive method for the duration of their study participation
- All patients and/or their parents or legal guardians must sign a written informed consent
- All institutional, food and drug administration (FDA), and National Cancer Institute (NCI) requirements for human studies must be met
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Aktiv komparator: Arm A (SOC treatment)
See detailed description |
Given IV
Andre navne:
Given IV
Andre navne:
Given IV
Andre navne:
Undergo bone marrow biopsy
Andre navne:
Given IV
Andre navne:
Given IV
Andre navne:
Undergo MRI
Andre navne:
Undergo ECHO
Andre navne:
Undergo MUGA
Andre navne:
Undergo bone marrow aspiration Given IV
Andre navne:
Undergo CT scan
Andre navne:
Given IV
Andre navne:
Undergo radiation therapy
Andre navne:
Undergo blood and urine sample collection
Andre navne:
Ancillary studies Given IV
Andre navne:
Given IV Given IV
Andre navne:
Given IV
Andre navne:
Undergo FDG PET
Andre navne:
Undergo stem cell infusion
Andre navne:
Given PO
Andre navne:
Undergo apheresis
Andre navne:
Undergo I-MIBG scan
Andre navne:
Given PO or via NG or G tube
Andre navne:
Undergo tumor resection surgery |
|
Eksperimentel: Arm B (Dinutuximab in induction)
See detailed description |
Given IV
Andre navne:
Given IV
Andre navne:
Given IV
Andre navne:
Undergo bone marrow biopsy
Andre navne:
Given IV
Andre navne:
Given IV
Andre navne:
Undergo MRI
Andre navne:
Undergo ECHO
Andre navne:
Undergo MUGA
Andre navne:
Undergo bone marrow aspiration Given IV
Andre navne:
Undergo CT scan
Andre navne:
Given IV
Andre navne:
Undergo radiation therapy
Andre navne:
Undergo blood and urine sample collection
Andre navne:
Ancillary studies Given IV
Andre navne:
Given IV Given IV
Andre navne:
Given IV
Andre navne:
Undergo FDG PET
Andre navne:
Undergo stem cell infusion
Andre navne:
Given PO
Andre navne:
Undergo apheresis
Andre navne:
Undergo I-MIBG scan
Andre navne:
Given PO or via NG or G tube
Andre navne:
Undergo tumor resection surgery |
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Event free survival (EFS)
Tidsramme: Up to 3 years
|
EFS time is calculated from time of randomization to Arms A or B to first episode of disease relapse or progression, second malignancy, or death, or until last contact if no event has occurred. |
Up to 3 years
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
End of Induction (EOI) response rate
Tidsramme: From randomization to end of extended Induction, up to 12 months
|
The response rate will be calculated among all evaluable patients at end of Induction. Responders are defined as patients who achieve a >= partial response per the revised 2017 International Neuroblastoma Response Criteria (INRC) |
From randomization to end of extended Induction, up to 12 months
|
|
Overall survival (OS)
Tidsramme: Up to 3 years
|
OS time is calculated from time of randomization to Arms A or B until death, or until last contact if patient is alive. |
Up to 3 years
|
|
Incidence of adverse events
Tidsramme: Up to 2 years
|
The proportion of patients with at least one grade 3 or higher non-hematologic toxicity or grade 4 or higher hematologic toxicity during protocol therapy, graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0, will be reported. |
Up to 2 years
|
|
GD2 expression
Tidsramme: Up to 12 months
|
Dinutuximab binding to pre-therapy patient tumor samples will be measured and categorized as high or low. |
Up to 12 months
|
Andre resultatmål
Andre resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Association between tumor and host factors and outcomes
Tidsramme: Up to 10 years
|
A series of univariate and multivariate Cox proportional hazards (for EFS and OS) and logistic regression (for responders vs. non-responders) models will be fit for patients in Arms A and B to evaluate the relationship between tumor and host factors (including tumor ALK and other somatic mutations, copy-number aberrations, gene fusions, gene expression, and pathogenic germline variants) and chemo-immunotherapy during Induction with outcome. |
Up to 10 years
|
|
Circulating biomarkers and markers of minimal residual disease
Tidsramme: Up to 10 years
|
Will be assessed by comparing the proportion of patients with detectable vs. non-detectable tumor markers (including circulating tumor deoxyribonucleic acid, circulating free DNA, circulating tumor cells, and immune function profiling) between Arms A and B during and after induction and post-consolidation therapy using chi-squared tests at each individual time point, and Cochran's Q across time points to determine if there is a consistent difference in proportions between arms across time. In addition, the tumor markers will be analyzed as continuous variables using longitudinal data analysis methodology such as mixed effects models or generalized estimating equations as appropriate. |
Up to 10 years
|
|
Patterns of failure
Tidsramme: Up to 10 years
|
The impact of early or late chemoimmunotherapy during Induction on the probability of the involvement of a specific disease site at first relapse will be evaluated using Fisher's exact test. |
Up to 10 years
|
|
Effect of telomere maintenance mechanisms
Tidsramme: Up to 10 years
|
A series of univariate and multivariate Cox proportional hazards (for EFS and OS) and logistic regression (for responders vs. non-responders) models will be fit for patients in arms A and B to evaluate the relationship between telomere maintenance mechanism and chemoimmunotherapy during Induction with outcome. Patients will be classified into 3 groups by telomere maintenance mechanism (TMM) based on messenger ribonucleic acid expression of TERT and analysis of telomeric DNA C-circles: telomerase (TERT) positive, alternative of lengthening of telomeres (ALT) positive, or no identified TMM. |
Up to 10 years
|
|
Functional and quality of life outcomes
Tidsramme: At serial time points during Induction, Extended Induction, Post-Consolidation, and at the end of therapy
|
Will descriptively summarize and compare the total Memorial Symptom Assessment Scale scores, total sub-domain scores, and individual symptom scores between patients randomized to receive dinutuximab during Induction (Arm B) to those of patients randomized to standard Induction (Arm A). |
At serial time points during Induction, Extended Induction, Post-Consolidation, and at the end of therapy
|
|
Adequacy of diagnostic biopsy specimens
Tidsramme: At time of tissue collection
|
Will be evaluated by descriptively comparing the successful delineation of histologic classification, MYCN amplification status, and ALK status via the traditional method of obtaining tissue for diagnosis, open surgical biopsy, versus the less invasive percutaneous core needle biopsy. |
At time of tissue collection
|
|
Associations between family-reported adverse social determinants of health and both clinical outcomes and biology
Tidsramme: Up to 10 years
|
Kaplan-Meier curves of EFS and OS will be generated and used to calculate 3-year EFS and OS estimates. Associations between social determinants of health (SDOH) and survival outcomes and time to receipt of dinutuximab will be evaluated with univariate and multivariate Cox proportional hazard models. Log-binomial regression will be used to estimate risk ratios and 95% CI for the occurrence of dinutuximab consent to randomization and therapy receipt by SDOH exposure. Effect modification of outcomes as a function of poverty, stratified by race/ethnicity, will be explored. |
Up to 10 years
|
|
Develop and validate deep learning predictors of Induction response (imaging objective)
Tidsramme: At diagnosis, EOI, during Extended Induction, and end of Extended Induction
|
Scans will be given as input to a convolutional neural network trained to predict EOI response. |
At diagnosis, EOI, during Extended Induction, and end of Extended Induction
|
|
Compare institutional versus central determination of overall response, individual response components, and PEIR and GEIR determination (imaging objective)
Tidsramme: Up to 10 years
|
Will be assessed by calculating the percentage of patients receiving the same EOI institutional and centrally reviewed determination of overall response, individual response components (primary tumor, soft tissue and bone metastatic disease, and bone marrow metastatic disease), and PEIR and GEIR. In addition, Cohen's kappa will be calculated to evaluate the concordance in each of these response measures. |
Up to 10 years
|
|
Incidence of late toxicities
Tidsramme: Up to 10 years
|
Will be addressed by calculating the proportion of treated patients with each late effect, including but not limited to impaired organ function, neuropsychiatric toxicity, and secondary malignancy. A 95% confidence interval will be placed on each proportion. |
Up to 10 years
|
|
Reduced dose radiotherapy to the primary site clinical target volume (CTV) in patients with complete response of the primary site at EOI results in comparable local control relative to historical cohorts
Tidsramme: Up to 10 years
|
The cumulative incidence of local progression (CILP) in patients with complete response of the primary site at EOI and GEIR on this study will be compared to the CILP rate of 11.2±1.8% observed on ANBL0532 using Gray's test. |
Up to 10 years
|
|
Post-transplant complications
Tidsramme: Up to 100 days post-transplant
|
Will be evaluated by calculating the incidence of endothelial injury complications and non-relapse mortality within 100 days of transplant, transplant-associated thrombotic microangiopathy (TA-TMA), severe TA-TMA, and sinusoidal obstruction syndrome (SOS) on Arms A and B and comparing between arms with a chi-squared test. The impact of TA-TMA occurrence on the timing or exclusion of subsequent therapy and interventions utilized to treat the TA-TMA, and associations with outcomes (EFS and OS) will be assessed. |
Up to 100 days post-transplant
|
|
Associations between end of induction (EOI) response and individual response components
Tidsramme: Up to 10 years
|
Log-rank tests will be used to explore the association between EOI response (using both the revised INRC and GEIR/PEIR classification) and individual response components (primary tumor, soft tissue and bone metastatic disease, and bone marrow metastatic disease) with outcome (EFS and OS). |
Up to 10 years
|
|
Changes in image-defined risk factors (IDRF)
Tidsramme: Up to 10 years
|
The proportion of patients in the analytic cohort for whom each particular IDRF and also the presence of any IDRF is absent prior to surgical resection will be computed. McNemar's test for paired observations will be applied to determine whether there is a difference in the proportion of each IDRF and any IDRF present before and after initial therapy, and conditional logistic regression will be used to compare between treatment arms A and B. The IDRF status after initial therapy and whether there has been a change from diagnosis will be associated with surgical outcome (complete vs. incomplete resection, presence or absence of surgical complications) using chi-squared tests, and compared between treatment arms A and B with the Cochran-Mantel-Haenszel test. The association of IDRF status with presence or absence of local failure after primary tumor resection will also be evaluated using a chi-squared test, and compared between treatment arms A and B with the Cochran-Mantel-Haenszel. |
Up to 10 years
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Efterforskere
Efterforskere
- Ledende efterforsker: Sara M Federico, Children's Oncology Group
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Anslået)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Neoplasmer
- Neoplasmer efter histologisk type
- Neoplasmer, kirtel og epitel
- Neoplasmer, Neuroepithelial
- Neuroektodermale tumorer
- Neoplasmer, kimceller og embryonale
- Neoplasmer, nervevæv
- Neuroektodermale tumorer, primitive, perifere
- Neuroektodermale tumorer, primitive
- Neuroblastom
- Ganglioneuroblastom
- Organisation og administration
- Sundhedstjenester Administration
- Aminosyrer, peptider og proteiner
- Organiske kemikalier
- Heterocykliske forbindelser, 1-ring
- Heterocykliske forbindelser
- Heterocykliske forbindelser, 2-ring
- Heterocykliske forbindelser, smeltet ring
- Undersøgelsesteknikker
- Terapeutik
- Kliniske laboratorieteknikker
- Diagnostiske teknikker og procedurer
- Diagnose
- Kirurgiske procedurer, operative
- Azoler
- Cytologiske teknikker
- Cytodiagnose
- Retinoider
- Carotenoider
- Polyener
- Alkener
- Kulbrinter, acyklisk
- Kulbrinter
- Cyclohexener
- Cyclohexanes
- Cycloparaffiner
- Kulbrinter, alicyklisk
- Kulbrinter, cyklisk
- Terpenes
- Pigmenter, biologisk
- Biologiske faktorer
- Kulhydrater
- Fysiske fænomener
- Camptothecin
- Alkaloider
- Podophyllotoxin
- Tetrahydronaphthalenes
- Naphthalenes
- Polycykliske aromatiske kulbrinter
- Kulbrinter, aromatisk
- Polycykliske forbindelser
- Glukosider
- Glycosider
- Dacarbazine
- Triazener
- Imidazoler
- Transplantation
- Indoler
- Uorganiske kemikalier
- Klorforbindelser
- Nitrogenforbindelser
- Koordinationskomplekser
- Aminosyrer
- Elementer
- Metaller
- Diagnostiske teknikker, kirurgisk
- Kemiteknikker, analytisk
- Spektrumanalyse
- Fosforamid -sennep
- Nitrogen sennepsforbindelser
- Sennepsforbindelser
- Kulbrinter, halogeneret
- Phosphoramider
- Organophosphorforbindelser
- Metaller, tung
- Vinca alkaloider
- Secologanin tryptamin alkaloider
- Indole alkaloider
- Indolizidiner
- Indolizines
- Anthracycliner
- Naphthacenes
- Aminoglycosider
- Platinforbindelser
- Daunorubicin
- Overgangselementer
- Celletransplantation
- Celle- og vævsbaseret terapi
- Biologisk terapi
- Cytaferese
- Fjernelse af blodkomponent
- Leukocytreduktionsprocedurer
- Celleseparation
- Phenylalanin
- Aminosyrer, aromatisk
- Aminosyrer, cykliske
- Hospitaladministration
- Sundhedsfacilitetsadministration
- Triethylenephosphoramid
- Aziridiner
- Aziriner
- Urologiske kirurgiske procedurer
- Urogenitale kirurgiske procedurer
- Temozolomid
- Irinotecan
- Cyclofosfamid
- Melphalan
- Etoposid
- Carboplatin
- Doxorubicin
- Vincristine
- Cisplatin
- Isotretinoin
- Thiotepa
- Topotecan
- 1,2-diaminocyclohexanplatin II-citrat
- Strålebehandling
- Stråling
- Biopsi
- Håndtering af eksemplar
- Magnetisk resonansspektroskopi
- Platinum
- Dinutuximab
- Stamcelletransplantation
- Hæmatopoietisk stamcelletransplantation
- Leukapherese
- Afdeling for nuklearmedicin, hospital
- Transuretral resektion af blære
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- NCI-2023-08530
- U10CA180886 (U.S. NIH-bevilling/kontrakt)
- NCI-2023-08530 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
- ANBL2131 (Anden identifikator: CTEP)
- ANBL2131 (Anden identifikator: Children's Oncology Group)
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
"NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page."
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
produkt fremstillet i og eksporteret fra U.S.A.
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .